(Q35857278)

10 August 2017

1 reference

title

Considering the role of four months of rifampin in the treatment of latent tuberculosis infection (English)

1 reference

10 August 2017

1 reference

1 reference

1 reference

Lee B Reichman

1

1 reference

10 August 2017

Alfred Lardizabal

series ordinal

2

1 reference

10 August 2017

Christopher H Hayden

series ordinal

3

1 reference

10 August 2017

language of work or name

English

0 references

publication date

5 August 2004

1 reference

American Journal of Respiratory and Critical Care Medicine

10 August 2017

1 reference

10 August 2017

170

1 reference

10 August 2017

8

1 reference

10 August 2017

832-835

1 reference

Isoniazid as preventive therapy in HIV-infected intravenous drug abusers. A decision analysis

10 August 2017

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Use of Isoniazid for Latent Tuberculosis Infection in a Public Health Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Whither short-course chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

The action of antituberculosis drugs in short-course chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Rifampin preventive therapy for tuberculosis in Boston's homeless.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Isoniazid-resistant tuberculosis. A community outbreak and report of a rifampin prophylaxis failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Randomized controlled trial of interventions to improve follow-up for latent tuberculosis infection after release from jail

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Cost-effectiveness of tuberculosis prophylaxis after release from short-term correctional facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

School-based screening for tuberculous infection. A cost-benefit analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200405-584PP

10.1164/RCCM.200405-584PP

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference